This Is A Low Bar For Alzheimer’s Researchers To Trip Over

A bit more about those “easy” problems scientists stubbornly refuse to solve

Writing in his column for i, my buddy Stuart Ritchie has a good take on the new Alzheimer’s drug donanemab, which the FDA is likely to decide whether to approve by the end of the year. On the basis of a new study just published in JAMA, donanemab is being treated as a major turning point in the fight against this neurodegenerative disease, and it comes …